Mast Cell Proteases Suppress Respiratory Viral Infections And Alleric Inflammation Of The Airways
Funder
National Health and Medical Research Council
Funding Amount
$665,532.00
Summary
Severe RSV infection and asthma accounts for poor quality of life in our community and current treatments have limited effects. Although the factors regulating these disorders are poorly understood, mast cells (MCs) may play important roles. We have shown MC protease-6 protects against viral infection. Here we will identify how MC and their factors are involved in the control of severe respiratory infections and allergic disease of the lung, and identify potential new ways to treat these conditi ....Severe RSV infection and asthma accounts for poor quality of life in our community and current treatments have limited effects. Although the factors regulating these disorders are poorly understood, mast cells (MCs) may play important roles. We have shown MC protease-6 protects against viral infection. Here we will identify how MC and their factors are involved in the control of severe respiratory infections and allergic disease of the lung, and identify potential new ways to treat these conditions.Read moreRead less
Targeting MicroRNA (miRNA) As A Unified Therapeutic Approach To The Treatment Of Asthma And Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$675,030.00
Summary
Approximately 30% of our community suffers from allergic inflammation (asthma/rhinitis/dermatitis) that results in poor quality of life. The factors regulating these disorders are poorly understood and current treatments only target the symptoms and not the cause of disease. MicroRNA control gene expression and are emerging as potential regulators of inflammation. This project will identify the role of microRNA in the regulation of allergic diseases and their potential as new therapeutic targets ....Approximately 30% of our community suffers from allergic inflammation (asthma/rhinitis/dermatitis) that results in poor quality of life. The factors regulating these disorders are poorly understood and current treatments only target the symptoms and not the cause of disease. MicroRNA control gene expression and are emerging as potential regulators of inflammation. This project will identify the role of microRNA in the regulation of allergic diseases and their potential as new therapeutic targets.Read moreRead less
Targeting MiRNA To Inhibit Leukocyte Differentiation: A Novel Anti-inflammatory Approach For The Treatment Of Asthma
Funder
National Health and Medical Research Council
Funding Amount
$601,386.00
Summary
In asthma, the symptoms are caused by an allergic reaction in the lung and the production of inflammatory cells whose maturation is guided by tiny molecules called “microRNAs”. The critical microRNAs will be identified and strategies to block their function developed and tested for their ability to inhibit allergic inflammation to evaluate this approach as a new treatment for asthma.
Understanding The Mechanisms Of Steroid Resistant Inflammatory Pathways In Mouse Models Of Asthma: Potential New Treatment Approaches
Funder
National Health and Medical Research Council
Funding Amount
$523,694.00
Summary
Steroids are used to treat asthma but some patients are resistant to therapy, and there is no effective treatment. Such patients suffer greater morbidity and mortality, and the heath care cost for clinical management is a significant economic burden. In this project we will obtain a better understanding of the mechanisms that regulate steroid-resistant components of disease, which control inflammation and narrowing of the airway. These studies will be central to the development of new therapies.
Chronic obstructive pulmonary disease (COPD) is a chronic lung condition caused by cigarette smoking. COPD consists of emphysema and chronic bronchitis, which lead to worsening breathlessness, cough and sputum production and need for oxygen. COPD is the third highest cause of burden of disease to the community in Australia and the fourth leading cause of death. People with COPD suffer many chest infections, which need antibiotics and offer need admission to hospital. However there is much variab ....Chronic obstructive pulmonary disease (COPD) is a chronic lung condition caused by cigarette smoking. COPD consists of emphysema and chronic bronchitis, which lead to worsening breathlessness, cough and sputum production and need for oxygen. COPD is the third highest cause of burden of disease to the community in Australia and the fourth leading cause of death. People with COPD suffer many chest infections, which need antibiotics and offer need admission to hospital. However there is much variability in the pattern of COPD related to infections. Natural chemicals produced by the body that fight infection are likely to be involved in this variability. Recently it has been discovered that there are variations in the genetic sequence of the genes that code for these chemicals. These genetic variations change the structure of the chemicals or the rate at which they are produced. Therefore it is highly likely that these genetic variations may influence the risk of developing COPD, and the risk of getting infections. In this study, we aim to systematically examine how these genetic variations alter the development of COPD and the risk of infections. At the start, we will collect a blood sample and phlegm (sputum) specimen from each person. The results of the genetic tests will then be compared to the risk of developing COPD, the chemicals produced and the risk of infection. We believe this study will improve our understanding of how COPD and its complications develop, leading to better treatment for this condition in the future.Read moreRead less
Investigatin The Causes Of Failed Efferocytosis In COPD-emphysema With A View To Identifying Novel Theraputic Targets
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
COPD is a leading cause of death. Smoking is the major cause of COPD and many sufferers are left with permanent damage and need ongoing treatment even after smoking cessation. Current treatments for COPD generally have limited efficacy. The project will identify the reason for the large number of dying cells and defective clearance of these cells that we have identified in the airways in COPD and study novel treatments that we hope will improve the health and well being of those with COPD.
Diagnostic Markers For Malignant Mesothelioma And Other Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$467,315.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year. We have been working on improving the tests available to detect this cancer and to follow the course of the disease with the aim of reducing patients' anxiety and health-care costs.
I am a clinical researcher determining: a) the role of altered airway structure, particularly airway smooth muscle and extracellular matrix, in asthma and COPD; and b) the prevalence of, and risk factors for, respiratory disease in general populations.
Improving Functional Capacity In Patients With Chronic Lung Disease With High Intensity Respiratory Muscle Training
Funder
National Health and Medical Research Council
Funding Amount
$340,880.00
Summary
Patients with chronic respiratory disease have limited exercise capacity, which severely impairs their quality of life. The mechanisms responsible for this impairment may relate to their lung disease, or to the long-term effects that inactivity has on the cardiovascular and musculoskeletal systems. Pulmonary rehabilitation programs involving whole-body exercise are now widely used as an addition to standard medical therapy as a way of decreasing symptoms and optimising function. While these gene ....Patients with chronic respiratory disease have limited exercise capacity, which severely impairs their quality of life. The mechanisms responsible for this impairment may relate to their lung disease, or to the long-term effects that inactivity has on the cardiovascular and musculoskeletal systems. Pulmonary rehabilitation programs involving whole-body exercise are now widely used as an addition to standard medical therapy as a way of decreasing symptoms and optimising function. While these generalised, broad-based programs result in modest improvements in peripheral muscle function, cardiovascular function, functional exercise capacity and quality of life, it is now apparent they have little or no effect on respiratory muscle function, which is also greatly impaired in COPD. The aims of this study are to answer two longstanding questions that are fundamental to rehabilitation programs in patients with COPD (i) does a program of specific respiratory muscle training alone improve whole-body exercise capacity, dyspnoea, and-or quality of life? and (ii) does the addition of a program of specific respiratory muscle training to a standard whole-body exercise rehabilitation program result in improvemed exercise capacity, dyspnoea and-or quality of life to a greater degree than a program of whole-body exercise training alone? The study is of importance to patients with COPD by investigating the mechanisms underlying the improvement in exercise capacity following a rehabilitation program and the role of respiratory muscle training in such a program. By more accurately defining the mechanisms of exercise limitation we may be able to maximise the benefits obtained during a rehabilitation program, including improved work capacity, reduction in the degree of breathlessness and improved quality of life.Read moreRead less
Surfactant Protein D As A Candidate Therapy In COPD
Funder
National Health and Medical Research Council
Funding Amount
$405,749.00
Summary
Smoking -related chronic bronchitis and emphysema, otherwise known COPD, costs the healthcare system over $800 million per year. People continue to suffer even after they have given up smoking, and the treatments available result in only modest improvements. COPD is associated with a a defect of the scavenging cells in the lung, which normally clear away dying cells, and some of the proteins ivolved in this process. We will investigate whether supplementing these proteins will help.